CAN BE
ALTERNATIVE
INVESTMENT

HT942524VRPFTTSA
Burzie C Baker III Grantor
Opening date 16 May 2024, 12:00AM
Closing date 8 Nov 2024, 12:00AM
Funding Opportunity Number: HT942524VRPFTTSA
Opportunity Category: Discretionary
Expected Number of Awards: 1
CFDA Number(s): 12.420 -- Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Posted Date: May 16, 2024 12:00:00 AM EDT
Closing Date: Nov 08, 2024 12:00:00 AM EST
Estimated Total Program Funding: 6400000
Award Ceiling: none
Award Floor: none
Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Agency Name: Burzie C Baker III Grantor
Description:
The FY24 VRP FTTSA is intended to support a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from military exposure (e.g., blast, blunt, thermal, chemical, directed energy trauma).
Key aspects of the FTTSA include:
• Overarching Challenge: Team science is a collaborative effort that leverages the strengths of investigators specializing in different fields to address an overarching scientific challenge or question. To identify an overarching challenge or question that meets the intent of the FTTSA, investigators are strongly encouraged to consider barrier(s) to and/or gap(s) in the understanding, prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military exposure and envision what may be achievable in 10 to 15 years. Based on the long-term expectation, investigators will identify what should and can be achieved in the short term and will design projects and research teams around these goals.
• Research Projects
○ Applications shall include at least three but no more than five distinct research projects that together form a concerted and synergistic effort to address the overarching challenge. Each project, as well as the overall effort, must align with one or more of the FY24 VRP Focus Areas. The potential topics of individual projects are wide-ranging. The examples provided below are illustrative and not exhaustive:
− Elucidation of molecular, cellular, and biophysical mechanisms of eye injury or visual dysfunction associated with military exposure
− Identification of significant changes in pathophysiology over time after military exposure to inform targeted treatments
− Identification of biomarkers and potential therapeutic targets
− Development and validation of therapeutic agents and/or devices
DOD FY24 Vision Focused Translational Team Science Award 5
− Development and validation of drug delivery platforms appropriate for eye injury or visual dysfunction associated with military exposure
− Development or improvement of clinically relevant trauma models
− Design of protection to mitigate the impact of military exposure on eye and vision
− Development of lightweight portable assessment or diagnostic capability
○ Individual projects must be capable of standing on their own scientific merits. The FY24 VRP FTTSA is not intended to support a series of research projects dependent on the success of any other project. Each project should propose a unique approach to address the overarching challenge and be capable of producing research findings with potential to impact the visual system trauma research field and/or patient care. Preliminary data to support the feasibility of each proposed research project are required.
○ Individual research projects may focus on any phase of research (e.g., basic, translational, applied, clinical, observational). The FY24 VRP FTTSA allows one of the projects to include a pilot clinical trial (PCT), but not a full-scale clinical trial. In contrast to full-scale clinical trials that are designed to determine safety or efficacy, the purpose of the PCT is to inform the feasibility, rationale, and design of subsequent clinical trials through limited clinical testing of a novel intervention. Applications that do include a PCT as part of the proposed research will have additional submission requirements and review criteria and should demonstrate sufficient understanding of regulatory approval requirements and the regulatory approval process.
• Implementation: The research strategy to address the overarching challenge should include a detailed implementation plan for participating research groups to coordinate efforts, facilitate collaboration, and create synergy through open and frequent communication, interaction, sharing of results/data/resources, and other means as applicable and necessary. The coordination, collaboration, and synergy are intended to advance a solution beyond what would be possible through individual efforts.
• Research Team: (New in FY24) The FY24 FTTSA is structured to have an Overall Lead Principal Investigator (PI) and multiple Project PIs. The Overall Lead PI will lead the overall effort as well as the execution of one project. The Overall Lead PI must have demonstrated success in leading large collaborative research project(s). Leaders of the other projects will be designated as Project PIs. Each PI may lead no more than one project.
o The Overall Lead PI will be responsible for the majority of the administrative tasks associated with application submission. Project PIs will have their own submission requirements. If recommended for funding, all PIs will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Overall Lead PI and Project PIs, refer to Section II.D.2, Content and Form of the Application Submission.
DOD FY24 Vision Focused Translational Team Science Award 6
o All key personnel should be committed to regular and open discussions of research plans, exchange of ideas, sharing of expertise and results, and other collaborative efforts. The CDMRP Science Officer assigned to a resulting award must be invited to participate in periodic research team meetings. The plan for such meetings should be noted in the application.
A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.
Studies that retrospectively analyze data generated from previously conducted clinical trial(s) are not considered a clinical trial.
For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:
(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.
(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.
(3) Outcomes research and health services research that do not fit under the definition of clinical trial.
Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.
Grantor Contact Information: CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Value Ad helps new businesses save 50% to 80% on essential services like marketing and
development. These savings act as an alternative investment, fueling growth.
Service providers gain valuable initial customers, helping them grow and attract investment.
It's a win-win for everyone!
This App/website is not affiliated with any government agency. We collect and organize information from publicly available government websites and provide direct links to these official sources.
For accurate details and to apply for grants or loans, please visit the relevant government websites linked within the App/website.
What is Value Ad?
Value Ad is an innovative policy designed to foster a mutually beneficial relationship between two key groups: new businesses and service providers. This policy helps startups save significantly on essential services while enabling service providers to gain valuable traction and growth opportunities.
How is it a Win-Win Deal?
For New Businesses:
Cost Savings: Startups can save 50% to 80% on essential services such as website development and marketing. This means they don’t need to invest heavily upfront, making it easier to launch and grow their business.
Alternative Investment: The money saved through these discounts can be reinvested into other critical areas of the business, acting as an alternative investment that fuels further growth and development.
For Service Providers:
Initial Customer Base: Service providers, often tech startups themselves, can attract a significant number of initial customers by offering their services at a discounted rate. This helps them build traction and demonstrate value, which is crucial for attracting venture capital (VC) funding and other opportunities.
Marketing Efficiency: By providing affordable services, service providers do not need to spend heavily on marketing to acquire new customers. The discounted services themselves become a powerful marketing tool, bringing in customers who can spread the word and enhance the provider’s reputation.
Growth and Expansion: Attracting more customers through Value Ad helps service providers expand their client base and build long-term relationships, which can lead to increased revenue and business growth.
Alternative Investment for New Businesses:
For new businesses, the significant cost savings achieved through the Value Ad policy effectively serve as an alternative investment. Instead of spending large amounts on website development and marketing, they can leverage the affordable services provided by service providers. The saved funds can be redirected into other strategic areas of the business, enhancing overall growth and sustainability.
Benefits for Service Providers:
Service providers benefit from the Value Ad policy by gaining access to a ready pool of new customers who are drawn by the discounted rates. This initial customer base is crucial for:
Building Traction: Demonstrating product or service viability to potential investors.
Securing Funding: Enhanced customer traction and a growing user base can make the service provider more attractive to venture capitalists and other funding sources.
Market Penetration: Establishing a presence in the market quickly and efficiently without heavy marketing expenditures.
In Summary:
Value Ad is a strategic policy designed to create a win-win scenario for both new businesses and service providers. By offering significant discounts on essential services, startups can save and reinvest those savings, while service providers gain crucial initial customers and market traction. This mutually beneficial arrangement supports the growth and success of both groups, making Value Ad a powerful tool for business development and investment.
We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.
We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.